Hunter Capital RTO 1 agrees to acquire ResoTher Pharma
Bitget2026/10/28 08:30- Hunter Capital RTO 1 has agreed to acquire Denmark's ResoTher Pharma in exchange for newly issued shares.
- The transaction values ResoTher Pharma at approximately SEK 273 million, implying a combined valuation of approximately SEK 333 million.
- ResoTher Pharma shareholders would own approximately 82% of the combined company; existing shareholders of the buyer would retain approximately 18%.
- Transaction-related financing totals approximately SEK 80 million, including a SEK 32 million convertible loan facility conditional on completion.
- The combined company will operate ResoTher Pharma's biotechnology business, with lead heart-attack treatment candidate RTP-026 preparing for a Phase 2b trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
